About the Study

The SOLARIS Study: Subcutaneous OLAnzapine Extended-Release Injection Study

This study is designed to evaluate the efficacy, safety, and tolerability of Olanzapine for extended-release injectable (TV-44749) for use as a treatment for adult patients with schizophrenia.
This study is sponsored by Teva Pharmaceutical Industries Ltd.

Length of Study: About 5 to 9 weeks of inpatient stay, with one year of outpatient visits to follow.

Eligibility 

You may be eligible to participate in this study if you:

• are between the ages of 18 – 65 years old
• have a diagnosis of schizophrenia
• recently experienced an increase in schizophrenia symptoms
• willing and able to stay overnight in our 24-hour observation

If chosen for this study, you will be compensated for every study visit that you complete and we can provide transportation if needed. 

If you are interested in participating in this clinical trial, please call our friendly staff at 773-989-8313 ext. 116 today. You can also fill out the contact form below.